Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

What happened

Labcorp reported third quarter 2026 revenue of $3.81 billion, up from $3.56 billion a year earlier. Adjusted EPS rose 14.5% to $4.78, and the company raised full-year 2026 revenue growth and adjusted EPS guidance.

Confirmed

Global impact / market context

Higher revenue and adjusted EPS mean Labcorp earns more profit per share, which supports the raised guidance. The four announced or closed transactions are expected to add to adjusted EPS in year one and return cost of capital by year three, tying deal spending to future profit.

Analyst inference

Labcorp's results show steady demand for laboratory testing and specialty tests for melanoma, Alzheimer's disease and hepatitis D. Raised guidance and acquisitions signal management expects growth to continue, which investors weigh against costs of integrating deals and regulatory approval risk.

Analyst inference

What to watch

1. Watch whether Labcorp meets its raised full-year 2026 guidance of 5.9% to 6.7% revenue growth and adjusted EPS of $18.30 to $18.70. Confirmed
2. Track the four acquisitions for first-year adjusted EPS gains and cost-of-capital returns by year three, since those outcomes determine whether the deal spending pays off. Proposed
3. Monitor adoption of the newly approved PGDx elio tissue complete CDx melanoma test, because specialty test sales carry higher profit per sale and support revenue growth. Analyst inference

Evidence

• Original source link unavailable